Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review.
Adult Onset Still's Disease
Autoimmune disease
Gating technique application
Radiotherapy
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
31
03
2019
revised:
02
02
2020
accepted:
16
03
2020
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
2
6
2020
Statut:
ppublish
Résumé
This manuscript focuses on the first experience in literature of a patient with a complicated Adult Onset Still's Disease-related heart failure who thereafter underwent adjuvant radiotherapy for left breast cancer. AOSD is a rare autoimmune inflammation-related disease, in which life-threatening pulmonary and cardiac complications can occur. In literature, AOSD is often associated with cancer, as paraneoplastic syndrome, but there are few data about primary AOSD and management of oncological therapies. A patient who needed adjuvant breast cancer radiotherapy underwent tumour board evaluation to define feasibility of an RT in a patient with of a history of a heart life-threatening complication 2 years before AOSD. Results of the review were discussed by a multidisciplinary panel of experts that chose the type of surgery, radiotherapy and monitoring of patient. Literature review confirmed association of AOSD with BC in some pts and uniqueness of this treatment management experience. Patient underwent RT according to schedule of 40.05/2.67 Gy/fx on residual left breast and 10/2 Gy/fx on tumour bed with the gating technique. The panel chose to keep immunosuppressive therapy with anakinra. No complications were observed at clinical, ECG and laboratory examinations. Maximum toxicity was G2 skin. At first follow up AOSD signs of flare were negative. In conclusion, when oncological treatments, especially radiotherapy, are mandatory for AOSD pts, multidisciplinary management and tailored monitoring are necessary to avoid acute adverse effects and allow pts to complete therapies.
Sections du résumé
AIM
OBJECTIVE
This manuscript focuses on the first experience in literature of a patient with a complicated Adult Onset Still's Disease-related heart failure who thereafter underwent adjuvant radiotherapy for left breast cancer.
BACKGROUND
BACKGROUND
AOSD is a rare autoimmune inflammation-related disease, in which life-threatening pulmonary and cardiac complications can occur. In literature, AOSD is often associated with cancer, as paraneoplastic syndrome, but there are few data about primary AOSD and management of oncological therapies.
MATERIALS AND METHODS
METHODS
A patient who needed adjuvant breast cancer radiotherapy underwent tumour board evaluation to define feasibility of an RT in a patient with of a history of a heart life-threatening complication 2 years before AOSD. Results of the review were discussed by a multidisciplinary panel of experts that chose the type of surgery, radiotherapy and monitoring of patient.
RESULTS
RESULTS
Literature review confirmed association of AOSD with BC in some pts and uniqueness of this treatment management experience. Patient underwent RT according to schedule of 40.05/2.67 Gy/fx on residual left breast and 10/2 Gy/fx on tumour bed with the gating technique. The panel chose to keep immunosuppressive therapy with anakinra. No complications were observed at clinical, ECG and laboratory examinations. Maximum toxicity was G2 skin. At first follow up AOSD signs of flare were negative.
CONCLUSION
CONCLUSIONS
In conclusion, when oncological treatments, especially radiotherapy, are mandatory for AOSD pts, multidisciplinary management and tailored monitoring are necessary to avoid acute adverse effects and allow pts to complete therapies.
Identifiants
pubmed: 32477018
doi: 10.1016/j.rpor.2020.03.013
pii: S1507-1367(20)30042-0
pmc: PMC7251537
doi:
Types de publication
Case Reports
Langues
eng
Pagination
527-532Informations de copyright
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Références
Lancet Oncol. 2005 Aug;6(8):557-65
pubmed: 16054566
BMC Med. 2017 Jan 6;15(1):5
pubmed: 28056958
Semin Arthritis Rheum. 2016 Apr;45(5):621-6
pubmed: 26581485
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):498-506
pubmed: 18164848
Rev Med Interne. 2008 Nov;29(11):936-9
pubmed: 18572281
Radiother Oncol. 2012 May;103(2):133-42
pubmed: 22391054
Mod Rheumatol. 2009;19(6):675-80
pubmed: 19609486
J Rheumatol. 2018 Jun;45(6):864-872
pubmed: 29657144
J Breast Cancer. 2012 Sep;15(3):337-43
pubmed: 23091547
Mod Rheumatol. 2019 Jul;29(4):704-707
pubmed: 27846765
J Med Case Rep. 2008 Aug 19;2:279
pubmed: 18710584
Gan To Kagaku Ryoho. 2015 Jun;42(6):759-62
pubmed: 26199253
J Rheumatol. 2009 Jun;36(6):1349-51
pubmed: 19509096
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Rev Esp Med Nucl. 2005 Sep-Oct;24(5):319-21
pubmed: 16194464
Expert Rev Clin Immunol. 2018 May;14(5):351-365
pubmed: 29658384
Nihon Kokyuki Gakkai Zasshi. 2006 Jul;44(7):499-503
pubmed: 16886806
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
JAMA Oncol. 2015 Oct;1(7):931-41
pubmed: 26247543
Am Heart J. 2007 Jun;153(6):1048-55
pubmed: 17540208
Mod Rheumatol. 2004;14(5):410-3
pubmed: 17143703
Radiother Oncol. 2019 Jun;135:147-152
pubmed: 31015161
Intern Med. 2005 Sep;44(9):994-7
pubmed: 16258220
Int J Inflam. 2012;2012:879020
pubmed: 22792508
Case Rep Rheumatol. 2016;2016:4232657
pubmed: 27092286
Mod Rheumatol. 2012 Sep;22(5):796-800
pubmed: 22270347
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e239-46
pubmed: 21640499
J Med Case Rep. 2016 Aug 02;10:212
pubmed: 27484255
Expert Rev Clin Immunol. 2017 Sep;13(9):849-866
pubmed: 28540751
Prensa Med Mex. 1979 May-Jun;44(5-6):85-96
pubmed: 555811
Int J Clin Exp Med. 2015 Oct 15;8(10):19581-5
pubmed: 26770614
Can Fam Physician. 1978 Nov;24:1203-4
pubmed: 21301567
Scand J Rheumatol. 2000;29(5):328-30
pubmed: 11093602
Medicine (Baltimore). 2016 Sep;95(36):e4357
pubmed: 27603335
Cancer Metastasis Rev. 2017 Jun;36(2):375-393
pubmed: 28707199
J Med Case Rep. 2008 Mar 06;2:73
pubmed: 18325097
J Korean Med Sci. 2004 Feb;19(1):137-41
pubmed: 14966357
Mod Rheumatol. 2018 Sep;28(5):736-757
pubmed: 29651907
Lung Cancer. 2009 Apr;64(1):124-6
pubmed: 19008012
Reumatologia. 2015;53(2):106-10
pubmed: 27407236
Radiat Oncol. 2013 Mar 12;8:57
pubmed: 23497676
J Rheumatol. 1993 Oct;20(10):1786-7
pubmed: 8295196
Clin Rheumatol. 2010 Feb;29(2):221-4
pubmed: 19847590
Ann Rheum Dis. 2004 Jul;63(7):887-8
pubmed: 15194592
Front Immunol. 2017 Jun 07;8:664
pubmed: 28638385
Neth J Med. 2016 Aug;74(7):324-5
pubmed: 27571955
Medicine (Baltimore). 2014 Mar;93(2):91-99
pubmed: 24646465
J Rheumatol. 1993 Oct;20(10):1788-92
pubmed: 8295197
Rev Med Interne. 1997;18(1):47-9
pubmed: 9092017
J Oral Maxillofac Surg. 2008 Jul;66(7):1492-5
pubmed: 18571037
Int J Hematol. 1993 Dec;59(1):53-7
pubmed: 8161735
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Anticancer Res. 2019 Apr;39(4):1667-1673
pubmed: 30952705
Diagn Cytopathol. 2015 Jan;43(1):60-5
pubmed: 24623571
Lupus. 2000;9(6):468-70
pubmed: 10981654
Expert Rev Anticancer Ther. 2018 Aug;18(8):793-803
pubmed: 29902386
J Am Acad Dermatol. 2015 Aug;73(2):294-303
pubmed: 26054431
Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):829-33
pubmed: 2777673
Taiwan Yi Xue Hui Za Zhi. 1984 May;83(5):491-8
pubmed: 6590781
J Rheumatol. 1992 Mar;19(3):424-30
pubmed: 1578458
Radiother Oncol. 2011 Aug;100(2):167-75
pubmed: 21752480
J Rheumatol. 1989 May;16(5):685-7
pubmed: 2666659
Scand J Rheumatol. 2015;44(4):309-14
pubmed: 25656459
Mod Rheumatol. 2001 Dec;11(4):336-9
pubmed: 24383780
Ryumachi. 2003 Jun;43(3):577-82
pubmed: 12910968
Acta Reumatol Port. 2014 Jan-Mar;39(1):98-9
pubmed: 24811471
Rev Bras Reumatol. 2013 Nov-Dec;53(6):532-4
pubmed: 24477732
Case Rep Rheumatol. 2015;2015:732095
pubmed: 25767733
BMC Cancer. 2011 Nov 16;11:487
pubmed: 22085873